DS
VKTX icon

David Shaw’s Viking Therapeutics VKTX Stock Holding History

David Shaw’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92M Buy
+74,900
New +$2.42M ﹤0.01% 2878
2026
Q1 		– Sell
-138,400
Closed -$4.87M – 5097
2025
Q4 		$4.87M Hold
138,400
– – ﹤0.01% 2320
2025
Q3 		$3.64M Buy
138,400
+114,900
+489% +$3.43M ﹤0.01% 2495
2025
Q2 		$623K Hold
23,500
– – ﹤0.01% 3540
2025
Q1 		$568K Sell
23,500
-30,000
-56% -$948K ﹤0.01% 3434
2024
Q4 		$2.15M Hold
53,500
– – ﹤0.01% 2666
2024
Q3 		$3.39M Buy
53,500
+3,500
+7% +$205K ﹤0.01% 2270
2024
Q2 		$2.65M Hold
50,000
– – ﹤0.01% 2386
2024
Q1 		$4.1M Buy
+50,000
New +$2.22M ﹤0.01% 2038

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

David Shaw's VKTX Position: Q2 2026 in Review

David Shaw reduced its Viking Therapeutics (VKTX) stake by 4.2% in Q2 2026, selling an estimated $2.28M and leaving 1,605,994 shares worth $62.6M. The position accounts for 0.03% of the portfolio, ranked #651.

David Shaw first reported a position in VKTX in Q2 2018 and has held it in 27 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • David Shaw held 1,605,994 shares of Viking Therapeutics worth $62.6M as of Q2 2026.
  • David Shaw sold 70,719 Viking Therapeutics shares in Q2 2026, an estimated $2.28M.
  • Viking Therapeutics made up 0.03% of David Shaw's portfolio in Q2 2026, its #651 holding.
  • David Shaw first reported a position in Viking Therapeutics in Q2 2018 and has held it in 27 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.